Tau oligomers as potential targets for immunotherapy for alzheimer's disease and tauopathies

Cristian Lasagna Reeves, D. L. Castillo-Carranza, G. R. Jackson, R. Kayed

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer disease (AD) and many neurodegenerative diseases. For a long time research has focused on neurofibrillary tangles (NFTs) and other large meta-stable inclusions composed of aggregated hyperphosphorylated tau protein. The correlation between these structures and disease progression produced conflicting results; moreover, the mechanism of their formation remains poorly understood. Lately, the significance and toxicity of NFTs have been challenged and a new aggregated tau entity has emerged as the true pathogenic species in tauopathies and a possible mediator of Aβ toxicity in AD; specifically, aggregates of a size intermediate between monomers and NFTs the so-called tau oligomers. Tremendous efforts have been devoted toward the optimization of a safe vaccine for AD by targeting Aβ peptide; despite the disappointing results, these studies produced a wealth of useful knowledge, which should be considered in developing taubased immunotherapy. Herein, we discuss the evidence supporting the critical role of tau oligomers in AD, the potential and challenges for targeting them by immunotherapy as a novel approach for AD treatment.

Original languageEnglish (US)
Pages (from-to)659-665
Number of pages7
JournalCurrent Alzheimer Research
Volume8
Issue number6
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Tauopathies
Immunotherapy
Alzheimer Disease
Neurofibrillary Tangles
tau Proteins
Microtubule-Associated Proteins
Neurodegenerative Diseases
Disease Progression
Vaccines
Peptides
Research

Keywords

  • Alzheimer disease
  • Immunotherapy
  • Neurodegeneration
  • Tau oligomers

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Tau oligomers as potential targets for immunotherapy for alzheimer's disease and tauopathies. / Lasagna Reeves, Cristian; Castillo-Carranza, D. L.; Jackson, G. R.; Kayed, R.

In: Current Alzheimer Research, Vol. 8, No. 6, 09.2011, p. 659-665.

Research output: Contribution to journalArticle

Lasagna Reeves, Cristian ; Castillo-Carranza, D. L. ; Jackson, G. R. ; Kayed, R. / Tau oligomers as potential targets for immunotherapy for alzheimer's disease and tauopathies. In: Current Alzheimer Research. 2011 ; Vol. 8, No. 6. pp. 659-665.
@article{511e5b8e4a1541bda7ae60bf5bf6c6f8,
title = "Tau oligomers as potential targets for immunotherapy for alzheimer's disease and tauopathies",
abstract = "The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer disease (AD) and many neurodegenerative diseases. For a long time research has focused on neurofibrillary tangles (NFTs) and other large meta-stable inclusions composed of aggregated hyperphosphorylated tau protein. The correlation between these structures and disease progression produced conflicting results; moreover, the mechanism of their formation remains poorly understood. Lately, the significance and toxicity of NFTs have been challenged and a new aggregated tau entity has emerged as the true pathogenic species in tauopathies and a possible mediator of Aβ toxicity in AD; specifically, aggregates of a size intermediate between monomers and NFTs the so-called tau oligomers. Tremendous efforts have been devoted toward the optimization of a safe vaccine for AD by targeting Aβ peptide; despite the disappointing results, these studies produced a wealth of useful knowledge, which should be considered in developing taubased immunotherapy. Herein, we discuss the evidence supporting the critical role of tau oligomers in AD, the potential and challenges for targeting them by immunotherapy as a novel approach for AD treatment.",
keywords = "Alzheimer disease, Immunotherapy, Neurodegeneration, Tau oligomers",
author = "{Lasagna Reeves}, Cristian and Castillo-Carranza, {D. L.} and Jackson, {G. R.} and R. Kayed",
year = "2011",
month = "9",
doi = "10.2174/156720511796717177",
language = "English (US)",
volume = "8",
pages = "659--665",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Tau oligomers as potential targets for immunotherapy for alzheimer's disease and tauopathies

AU - Lasagna Reeves, Cristian

AU - Castillo-Carranza, D. L.

AU - Jackson, G. R.

AU - Kayed, R.

PY - 2011/9

Y1 - 2011/9

N2 - The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer disease (AD) and many neurodegenerative diseases. For a long time research has focused on neurofibrillary tangles (NFTs) and other large meta-stable inclusions composed of aggregated hyperphosphorylated tau protein. The correlation between these structures and disease progression produced conflicting results; moreover, the mechanism of their formation remains poorly understood. Lately, the significance and toxicity of NFTs have been challenged and a new aggregated tau entity has emerged as the true pathogenic species in tauopathies and a possible mediator of Aβ toxicity in AD; specifically, aggregates of a size intermediate between monomers and NFTs the so-called tau oligomers. Tremendous efforts have been devoted toward the optimization of a safe vaccine for AD by targeting Aβ peptide; despite the disappointing results, these studies produced a wealth of useful knowledge, which should be considered in developing taubased immunotherapy. Herein, we discuss the evidence supporting the critical role of tau oligomers in AD, the potential and challenges for targeting them by immunotherapy as a novel approach for AD treatment.

AB - The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer disease (AD) and many neurodegenerative diseases. For a long time research has focused on neurofibrillary tangles (NFTs) and other large meta-stable inclusions composed of aggregated hyperphosphorylated tau protein. The correlation between these structures and disease progression produced conflicting results; moreover, the mechanism of their formation remains poorly understood. Lately, the significance and toxicity of NFTs have been challenged and a new aggregated tau entity has emerged as the true pathogenic species in tauopathies and a possible mediator of Aβ toxicity in AD; specifically, aggregates of a size intermediate between monomers and NFTs the so-called tau oligomers. Tremendous efforts have been devoted toward the optimization of a safe vaccine for AD by targeting Aβ peptide; despite the disappointing results, these studies produced a wealth of useful knowledge, which should be considered in developing taubased immunotherapy. Herein, we discuss the evidence supporting the critical role of tau oligomers in AD, the potential and challenges for targeting them by immunotherapy as a novel approach for AD treatment.

KW - Alzheimer disease

KW - Immunotherapy

KW - Neurodegeneration

KW - Tau oligomers

UR - http://www.scopus.com/inward/record.url?scp=80051517143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051517143&partnerID=8YFLogxK

U2 - 10.2174/156720511796717177

DO - 10.2174/156720511796717177

M3 - Article

VL - 8

SP - 659

EP - 665

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 6

ER -